Compare AbbVie Inc (ABBV) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while GraniteShares 2x Long NVDA Daily ETF trades at $30.69. The key difference: AbbVie Inc pays a 2.72% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and AbbVie Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | NVDL | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $43.02 |
52-Week Low | $184.85 | $21.76 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $28.53 with a 1.1% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has demonstrated significant volatility, with a 12% single-day drop in early June 2026 highlighting the risks of daily leverage reset. Recent stock splits (1:3 on June 25-26, 2026) have adjusted share structure.
The outlook for NVDL remains tied to NVIDIA's performance and AI sector momentum. While the ETF offers leveraged exposure to NVDA's gains, it carries substantial risk from daily rebalancing during market downturns. Investors should weigh the potential for amplified returns against the documented volatility and structural risks of leveraged ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
